Functional cure with single agent olutasidenib in relapsed IDH1/NPM1 co-mutated AML by Justin Watts, Tiffany Nong, Katarina Micin, Deborah Soong, Ellen Madarang, Maurizio Affer, Shefali Mehra, Jessica Alvarez Lesmes, Jennifer Chapman, Yi Zhou, Amber Thomassen, Terrence Bradley, Tulasigeri Totiger, Ronan Swords, Justin Taylor

Get full text

Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy by Reid Shaw, James J. Yoon, Hannah Johnston, Marta B. Davidson, Alexa J. Siddon, Rory M. Shallis, Evan C. Chen, Madelyn Burkart, Timothy S. Oh, Sunil G. Iyer, Ellen Madarang, Chandrasekar Muthiah, Joshua Kassner, Raajit K. Rampal, Guru Subramanian Guru Murthy, Terrence Bradley, Yasmin Abaza, Jacqueline S. Garcia, Vikas Gupta, Kristen M. Pettit, Olatoyosi Odenike, Anand A. Patel

Get full text

Response and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms by Leah A. Goldberg, James J. Yoon, Hannah Johnston, Marta B. Davidson, Alexa Siddon, Rory M. Shallis, Evan C. Chen, Madelyn Burkart, Timothy S. Oh, Sunil G. Iyer, Ellen Madarang, Chandrasekar Muthiah, Joshua Kassner, Raajit K. Rampal, Guru Subramanian Guru Murthy, Terrence Bradley, Yasmin Abaza, Jacqueline S. Garcia, Vikas Gupta, Kristen M. Pettit, Olatoyosi Odenike, John F. Cursio, Anand A. Patel

Get full text